文献速递药物不良反应与药物警戒

VigiBase妊娠算法在药物警戒病例报告数据库中的综合评估

Uncovering Pregnancy Exposures in Pharmacovigilance Case Report Databases: A Comprehensive Evaluation of the VigiBase Pregnancy Algorithm.
PubMed 文献 · Drug Saf · 2025-06-23

本研究评估了VigiBase中基于规则识别妊娠暴露病例的妊娠算法,以人工标注为金标准,并与MedDRA的SMQ「妊娠及新生儿主题(窄)」比较。在7874份标注报告中,算法召回率75%(95%CI 69-80),限制于符合ICH E2B格式的报告时升至91%(95%CI 86-95);在30000份随机样本中精确度92%(95%CI 88-95),均优于SMQ基线。

要点

  • VigiBase妊娠算法召回率75%,符合ICH E2B格式报告时达91%。
  • 算法精确度92%,高于SMQ基线的74%。
  • 假阴性主要源于妊娠术语未完整映射至MedDRA及信息仅存于自由文本。

核心结论

  • VigiBase妊娠算法表现稳健,有助于促进妊娠相关药物警戒工作。
  • 该评估为未来研究建立了有价值的基准,并强调需全球统一妊娠暴露报告标准。

研究设计与样本

  • 基于规则的算法利用ICH E2B传输格式中多个结构化数据元素判断病例是否为妊娠病例,不考虑自由文本信息。
  • 使用三个数据集评估:截至2023年1月的去重VigiBase全数据集、排除45岁及以上个体及18岁及以上男性的降采样数据集(评估召回率)、全数据集随机样本(评估精确度)。
  • 以SMQ「妊娠及新生儿主题(窄)」为基线,对降采样数据集全部报告及随机数据集中被算法或SMQ标记为妊娠病例的报告进行人工标注作为金标准。

主要发现

  • 降采样数据集含7874份标注报告,其中253份为妊娠病例,算法召回75%(95%CI 69-80),限制于符合ICH E2B格式的报告时召回91%(95%CI 86-95)。
  • SMQ基线召回率较低,为62%(95%CI 56-68)。
  • 随机数据集含30000份报告,算法标记344份,其中316份标注为妊娠病例,精确度92%(95%CI 88-95)。
  • SMQ基线精确度较低,为74%(95%CI 69-78)。
  • 假阴性主要源于特定妊娠术语未完整映射至MedDRA,其次是妊娠信息仅存于自由文本;假阳性主要原因为产后适应症、非妊娠特异性事件或信息误编码为妊娠相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Information on the safety of medicine use during pregnancy is limited at the time of marketing, making post-marketing surveillance essential. However, the lack of a specific indicator for pregnancy-related case reports within the international standard for transmission of individual case safety reports complicates the retrieval of such reports in pharmacovigilance databases. To address this, an algorithm to identify reports of exposures during pregnancy was developed in VigiBase, the World Health Organization global database of adverse event reports. OBJECTIVE: We aimed to evaluate and characterise the VigiBase pregnancy algorithm. METHODS: The rule-based algorithm uses multiple structured data elements in the International Council of Harmonisation (ICH) E2B transmission format that could potentially hold pregnancy-related information, to determine if a case report qualifies as a pregnancy case. Free text information is not considered. Three datasets were used for the evaluation. The "Full dataset" comprised deduplicated VigiBase data up to January 2023. The "Downsampled dataset" was a subsample of the Full dataset, adjusted to increase the prevalence of pregnancy reports by excluding individuals aged 45 years or older and male individuals aged 18 years or older, used to evaluate recall (i.e. sensitivity). The "Random dataset" was a straight random sample of the Full dataset, used to evaluate precision (i.e. positive predictive value). As a baseline for comparison, the Standardised Medical Dictionary for Regulatory Activities (MedDRA®) Query (SMQ) "Pregnancy and neonatal topics (narrow)" was used. To provide a gold standard for the evaluation, case reports were manually annotated as either "pregnancy case" or "non-pregnancy case", for all reports in the Downsampled dataset, and for the reports flagged as pregnancy cases by the algorithm or the SMQ baseline in the Random dataset. RESULTS: In the Downsampled dataset with 7874 annotated reports, 253 reports were annotated as pregnancy cases. Of those, the algorithm recalled 75% (95% confidence interval [CI] 69-80), increasing to 91% (95% CI 86-95) when restricting the analysis to reports adhering to the ICH E2B format. Preprocessing obstacles of incomplete mapping of specific pregnancy terms to MedDRA® led to most false negatives followed by pregnancy information confined to free text information. The SMQ baseline had a lower recall of 62% (95% CI 56-68). In the Random dataset with 30,000 reports, the algorithm flagged 344 reports, among which 316 were annotated as pregnancy cases, leading to a precision of 92% (95% CI 88-95). The main reasons for false positives were postpartum indications, non-pregnancy-specific events or information miscoded as pregnancy related. The SMQ baseline had a lower precision of 74% (95% CI 69-78). CONCLUSIONS: The VigiBase pregnancy algorithm demonstrates robust performance, highlighting its potential to facilitate pharmacovigilance related to pregnancy. Our evaluation establishes a valuable benchmark for future research and emphasises the need for global harmonisation of standards for reporting pregnancy exposures.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Sandberg L, Vidlin SH, K-Pápai L, et al. Uncovering Pregnancy Exposures in Pharmacovigilance Case Report Databases: A Comprehensive Evaluation of the VigiBase Pregnancy Algorithm. Drug Saf. 2025. PMID: 40549134. doi:10.1007/s40264-025-01559-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。